Inovio Pharmaceuticals has completed enrolment in a Phase I/II clinical trial of a INO-5401 combination to treat patients with newly diagnosed glioblastoma (GBM).

The trial involves a combination of INO-5401, INO-9012 and cemiplimab-rwlc (Libtayo or REGN2810).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

INO-5401 is a T cell activating immunotherapy designed to encode various antigens expressed by GBM, while INO-9012 is an immune activator encoding IL-12.

Cemiplimab-rwlc is a PD-1 inhibitor co-developed by Regeneron Pharmaceuticals and Sanofi.

The open-label, multi-centre Phase I/II trial will assess the safety, immunogenicity and preliminary efficacy of the combination in 52 participants.

“This is an important step for Inovio’s cancer combination strategy using our T cell-generating therapies in combination with PD-1/PD-L1 inhibitors.”

INO-5401 and INO-9012 will be administered intramuscularly after electroporation (EP) in combination with cemiplimab and chemoradiation and radiation.

The primary outcome measure of the trial is the proportion of subjects with adverse events, while secondary outcomes include overall survival and a change in antigen-specific humoral response from baseline.

Interim data is expected to be available by the end of this year, and the trial is set to be completed in January 2021.

Inovio Pharmaceuticals president and CEO Joseph Kim said: “This is an important step for Inovio’s cancer combination strategy using our T cell-generating therapies in combination with PD-1/PD-L1 inhibitors for GBM and for multiple other cancers to improve overall efficacy of immunotherapy.

“In this GBM trial, our goal is to increase the overall survival of patients facing a disease where neither the standard of care, nor clinical outcomes have changed in a clinically significant way in more than a decade.”

Glioblastoma is an aggressive form of brain cancer. Patients on standard of care are said to have a median overall survival of approximately 15 months, with the average five-year survival rate being less than 5%.